Evidence map›Paper›PMID 35477770›Full record

ArticleCancer gene therapy2022

Description and optimization of a multiplex bead-based flow cytometry method (MBFCM) to characterize extracellular vesicles in serum samples from patients with hematological malignancies.

Lin Li, André Görgens, Veronika Mussack, Elena Pepeldjiyska, Anne Sophie Hartz, Andreas Rank, Jörg Schmohl, Doris Krämer, Samir El Andaloussi, Michael W Pfaffl and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Cancer gene therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Extracellular Vesicle Preparation and Analysis: A State-of-the-Art Review.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Lin Li *Working-group: Immune-Modulation, Medical Department III, University Hospital of Munich, Munich, Germany. Lin.Li@med.uni-muenchen.de.
André Görgens *Department of Laboratory Medicine, Division of Biomolecular and Cellular Medicine, Karolinska Institutet, Stockholm, Sweden.
Veronika MussackDepartment of Animal Physiology and Immunology, TUM School of Life Sciences Weihenstephan, Technical University of Munich, Freising, Germany.ORCID http://orcid.org/0000-0002-4539-9313
Elena PepeldjiyskaWorking-group: Immune-Modulation, Medical Department III, University Hospital of Munich, Munich, Germany.
Anne Sophie HartzWorking-group: Immune-Modulation, Medical Department III, University Hospital of Munich, Munich, Germany.
Andreas RankDepartment of Hematology and Oncology, University Hospital of Augsburg, Augsburg, Germany.
Jörg SchmohlDepartment of Hematology and Oncology, Hospital of Stuttgart, Stuttgart, Germany.
Doris KrämerDepartment of Heamatology, Oncology and Palliative Care, Ameos Klinikum Mitte, Bremerhaven, Germany.
Samir El AndaloussiDepartment of Laboratory Medicine, Division of Biomolecular and Cellular Medicine, Karolinska Institutet, Stockholm, Sweden.
Michael W PfafflDepartment of Animal Physiology and Immunology, TUM School of Life Sciences Weihenstephan, Technical University of Munich, Freising, Germany.ORCID http://orcid.org/0000-0002-3192-1019
Helga SchmetzerWorking-group: Immune-Modulation, Medical Department III, University Hospital of Munich, Munich, Germany. Helga.Schmetzer@med.uni-muenchen.de.ORCID http://orcid.org/0000-0001-7058-2446
München Klinik · DEKarolinska Institutet · SETechnical University of Munich · DEKlinikum Stuttgart · DEUniversity Hospital Augsburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extracellular Vesicles (EVs) are membranous vesicles produced by all cells under physiological and pathological conditions. In hematological malignancies, tumor-derived EVs might reprogram the bone marrow environment, suppress antileukemic immunity, mediate drug resistance and interfere with immunotherapies. EVs collected from the serum of leukemic samples might correlate with disease stage, drug-/immunological resistance, or might correlate with antileukemic immunity/immune response. Special EV surface protein patterns in serum have the potential as noninvasive biomarker candidates to distinguish several disease-related patterns ex vivo or in vivo. EVs were isolated from the serum of acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), chronic lymphoid leukemia (CLL) patients, and healthy volunteers. EVs were characterized by transmission electron microscopy and fluorescence nanoparticle tracking analysis, and EV surface protein profiles were analyzed by multiplex bead-based flow cytometry to identify tumor- or immune system-related EVs of AML, ALL, CLL, and healthy samples. Aiming to provide proof-of-concept evidence and methodology for the potential role of serum-derived EVs as biomarkers in leukemic versus healthy samples in this study, we hope to pave the way for future detection of promising biomarkers for imminent disease progression and the identification of potential targets to be used in a therapeutic strategy.

Indexed as

Extracellular VesiclesHematologic NeoplasmsLeukemia, Lymphocytic, Chronic, B-CellLeukemia, Myeloid, AcuteBiomarkersFlow CytometryHumansMembrane ProteinsBiomarkersMembrane Proteins

Identifiers

PMID35477770
PMCPMC9663305
OpenAlexW4225085546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.